RPRX(Royalty Pharma plc) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $2.29B | $2.24B | $2.35B | $2.26B | $2.38B |
| 毛利润 | — | — | — | — | — |
| 营业利润 | $1.43B | $307.06M | $1.49B | $1.29B | $1.56B |
| 净利润 | $619.73M | $42.83M | $1.13B | $858.98M | $770.95M |
| 经营现金流 | $2.02B | $2.14B | $2.99B | $2.77B | $2.49B |
| 自由现金流 | — | — | — | — | — |
| 摊薄每股收益 | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |